UCB FY 2023 Results Earnings Call February 2024

UCB presented its FY 2023 financial results and strategic growth initiatives during a capital markets earnings call on February 28, 2024. The presentation outlines the company's innovation pipeline, including BIMZELX® as a key growth driver, and demonstrates a foundation for a decade of sustainable growth through differentiated immunology and neurology assets.